Your gist is correct, Biotech is about development of product and just as importantly effective commercialisation of that developed product. The appointment of SC, TL and the new CFO by ND is about that effective commercialisation which will in turn lead to a share price that reflects that effectiveness. So if they get that right the options will look after themselves.
As far as TB on the board, that's the last place we want her, let her focus on what she does best, the science and its development!
ACL Price at posting:
64.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)